Recently, Danish pharmaceutical giant Novo Nordisk announced that its novel GLP-1 receptor agonist for the treatment of adult type 2 diabetes—semaglutide injection (brand name: Ozempic)—has officially received approval from China’s National Medical Products Administration (NMPA). Administered via once-weekly subcutaneous injection, the drug effectively improves glycemic control and demonstrates significant weight-loss benefits. Clinical studies have shown that semaglutide not only lowers HbA1c levels but also reduces the risk of cardiovascular events, offering a more comprehensive therapeutic option for patients with type 2 diabetes. This approval marks Novo Nordisk’s deeper strategic commitment to diabetes care in China and reflects the country’s accelerated adoption of innovative therapies. With the rising prevalence of diabetes in China, the launch of this medication is expected to benefit tens of millions of patients and enhance chronic disease management. Additionally, semaglutide is being explored globally for other indications such as obesity, suggesting its potential to address a broader range of health conditions in the future.
近日，丹麦制药巨头诺和诺德（Novo Nordisk）宣布，其用于治疗成人2型糖尿病的新型GLP-1受体激动剂——司美格鲁肽注射液（商品名：Ozempic）已正式获得中国国家药品监督管理局（NMPA）批准上市。该药物通过每周一次皮下注射给药，可有效改善血糖控制，并具有显著减重效果。临床研究表明，司美格鲁肽不仅能降低糖化血红蛋白（HbA1c）水平，还能减少心血管事件风险，为2型糖尿病患者提供更全面的治疗选择。此次获批标志着诺和诺德在中国糖尿病治疗领域进一步深化布局，也反映出中国对创新疗法的加速引进。随着中国糖尿病患病率持续攀升，该药物的上市有望惠及数千万患者，提升慢病管理质量。此外，司美格鲁肽在全球范围内还被探索用于肥胖症等适应症，未来或将在更多疾病领域发挥潜力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/4936.html